Loading
Life sciences · Journal article
Frontiers in Oncology · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Multiple primary malignancies (MPMs) are increasingly encountered in clinical practice as cancer survivorship improves. The coexistence of colorectal cancer (CRC) and lymphoma is rare, and long-term survival exceeding 10 years in such patients has seldom been reported. Case presentation We report a 63-year-old male patient who presented with sigmoid colon adenocarcinoma with synchronous multiple liver metastases (cT4N1M1, Stage IV) in 2015. Molecular testing of the primary sigmoid colon tumor specimen revealed wild-type KRAS, NRAS, BRAF, and PIK3CA.After multidisciplinary team (MDT) discussion, the patient received 4 cycles of FOLFIRI regimen chemotherapy as conversion therapy, achieving partial response (PR). He subsequently underwent special hepatic segmentectomy and laparoscopic-assisted radical sigmoidectomy, followed by additional chemotherapy. Evaluation in May 2016 showed complete response (CR) with no evidence of disease (NED). During regular follow-up in 2021, a left inguinal lymph node enlargement was detected. Biopsy confirmed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), CD30-positive. The patient received 6 cycles of CHOP chemotherapy combined with local radiotherapy, achieving CR. In March 2026, retroperitoneal lymph node recurrence was confirmed, and continued chemotherapy was recommended. The patient has achieved an overall survival of over 10 years since the initial CRC diagnosis. Conclusion This case suggests that, with MDT-guided individualized treatment, long-term survival may be achievable in patients with advanced CRC and liver metastases following conversion therapy and radical surgery. The subsequent development of a second primary PTCL-NOS highlights the importance of vigilant long-term surveillance in cancer survivors. This report adds to the limited literature on MPMs involving CRC and lymphoma with extended survival.